Azmi Nabulsi, M.D., is the former Deputy Chief Medical Officer, Chief Scientific Officer and Head of Global Development at Takeda Pharmaceuticals. In these roles, he led all global research and development, medical, regulatory, operations, and data analytics functions. In addition, he led research and development portfolio management strategy and planning, focusing on enhancing the company’s pipeline and productivity.
During his 14-year career at Takeda U.S. and Japan, Dr. Nabulsi oversaw global drug development for both early and late-stage product candidates, and he was responsible for bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market. He was also responsible for the design and execution of the company’s major research and development transformation, utilizing industry-leading approaches to drive innovation. Dr. Nabulsi has led or directed partnerships and alliances in gastroenterology, oncology, immunology, cardiovascular medicine, and metabolism. Prior to Takeda, he held leadership positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures. He currently serves on the Board of ReAlta Life Sciences, Inc.
Dr. Nabulsi has an M.D. from Ain-Shams University in Cairo and an M.P.H. from the University of Minnesota.
What is Azmi Nabulsi's net worth?
The estimated net worth of Azmi Nabulsi is at least $1.10 million as of April 11th, 2023. Dr. Nabulsi owns 99,567 shares of Phathom Pharmaceuticals stock worth more than $1,100,215 as of March 27th. This net worth estimate does not reflect any other investments that Dr. Nabulsi may own. Additionally, Dr. Nabulsi receives a salary of $815,210.00 as COO at Phathom Pharmaceuticals. Learn More about Azmi Nabulsi's net worth.
What is Azmi Nabulsi's salary?
As the COO of Phathom Pharmaceuticals, Inc., Dr. Nabulsi earns $815,210.00 per year. The highest earning executive at Phathom Pharmaceuticals is Ms. Terrie J. Curran, President, CEO & Director, who commands a salary of $1,110,000.00 per year. Learn More on Azmi Nabulsi's salary.
How do I contact Azmi Nabulsi?
Has Azmi Nabulsi been buying or selling shares of Phathom Pharmaceuticals?
Azmi Nabulsi has not been actively trading shares of Phathom Pharmaceuticals in the last ninety days. Most recently, on Tuesday, April 11th, Azmi Nabulsi bought 10,000 shares of Phathom Pharmaceuticals stock. The stock was acquired at an average cost of $8.26 per share, with a total value of $82,600.00. Following the completion of the transaction, the chief operating officer now directly owns 99,567 shares of the company's stock, valued at $822,423.42. Learn More on Azmi Nabulsi's trading history.
Who are Phathom Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Phathom Pharmaceuticals?
During the last year, Phathom Pharmaceuticals insiders bought shares 5 times. They purchased a total of 27,419 shares worth more than $218,716.58. During the last year, insiders at the sold shares 7 times. They sold a total of 3,746,862 shares worth more than $30,387,835.95. The most recent insider tranaction occured on March, 22nd when insider Terrie Curran sold 16,851 shares worth more than $153,512.61. Insiders at Phathom Pharmaceuticals own 7.5% of the company.
Learn More about insider trades at Phathom Pharmaceuticals. Information on this page was last updated on 3/22/2024.